(Q42999649)

English

Induction Pegylated Interferon Alfa-2a and High Dose Ribavirin Do Not Increase SVR in Heavy Patients With HCV Genotype 1 and High Viral Loads

scientific article published on September 30, 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Induction pegylated interferon alfa-2a and high dose ribavirin do not increase SVR in heavy patients with HCV genotype 1 and high viral loads (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Induction Pegylated Interferon Alfa-2a and High Dose Ribavirin Do Not Increase SVR in Heavy Patients With HCV Genotype 1 and High Viral Loads (English)

1 reference

10.1053/J.GASTRO.2010.08.051

https://api.crossref.org/works/10.1053/J.GASTRO.2010.08.051

6 July 2024

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

pegylated interferon

1 reference

based on heuristic

inferred from title

K. Rajender Reddy

1

object named as

K Rajender Reddy

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Dzhamal Abdurakhmanov

5

object named as

Djamal Abdurakhmanov

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20816836

6 July 2024

6

object named as

Igor Bakulin

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20816836

6 July 2024

Giovanni Faria Silva

8

object named as

Giovanni Faria Silva

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20816836

6 July 2024

author name string

Maribel Rodriguez-Torres

3

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Hugo Cheinquer

4

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Viacheslav Morozov

7

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Natalia Geyvandova

9

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Carol Stanciu

10

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Michael Rabbia

11

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Michael McKenna

12

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

PROGRESS Study Investigators

15

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Mitchell L. Shiffman

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20816836

6 July 2024

James A. Thommes

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20816836

6 July 2024

Stephen A. Harrison

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20816836

6 July 2024

language of work or name

0 references

publication date

30 September 2010

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

full work available at URL

https://api.elsevier.com/content/article/PII:S0016508510013016?httpAccept=text/xml

1 reference

10.1053/J.GASTRO.2010.08.051

https://api.crossref.org/works/10.1053/J.GASTRO.2010.08.051

6 July 2024

https://api.elsevier.com/content/article/PII:S0016508510013016?httpAccept=text/plain

1 reference

10.1053/J.GASTRO.2010.08.051

https://api.crossref.org/works/10.1053/J.GASTRO.2010.08.051

6 July 2024

Gastroenterology

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

139

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

1972-1983

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Diagnosis, management, and treatment of hepatitis C: an update

1

1 reference

10.1053/J.GASTRO.2010.08.051

https://api.crossref.org/works/10.1053/J.GASTRO.2010.08.051

6 July 2024

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

2

1 reference

10.1053/J.GASTRO.2010.08.051

https://api.crossref.org/works/10.1053/J.GASTRO.2010.08.051

6 July 2024

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

3

1 reference

10.1053/J.GASTRO.2010.08.051

https://api.crossref.org/works/10.1053/J.GASTRO.2010.08.051

6 July 2024

Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites

4

1 reference

10.1053/J.GASTRO.2010.08.051

https://api.crossref.org/works/10.1053/J.GASTRO.2010.08.051

6 July 2024

Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C.

5

1 reference

10.1053/J.GASTRO.2010.08.051

https://api.crossref.org/works/10.1053/J.GASTRO.2010.08.051

6 July 2024

Telaprevir and peginterferon with or without ribavirin for chronic HCV infection

6

1 reference

10.1053/J.GASTRO.2010.08.051

https://api.crossref.org/works/10.1053/J.GASTRO.2010.08.051

6 July 2024

Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients.

7

1 reference

10.1053/J.GASTRO.2010.08.051

https://api.crossref.org/works/10.1053/J.GASTRO.2010.08.051

6 July 2024

Hepatic steatosis in chronic hepatitis C: baseline host and viral characteristics and influence on response to therapy with peginterferon alpha-2a plus ribavirin

8

1 reference

10.1053/J.GASTRO.2010.08.051

https://api.crossref.org/works/10.1053/J.GASTRO.2010.08.051

6 July 2024

Impact of obesity, steatosis and insulin resistance on progression and response to therapy of hepatitis C.

9

1 reference

10.1053/J.GASTRO.2010.08.051

https://api.crossref.org/works/10.1053/J.GASTRO.2010.08.051

6 July 2024

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

10

1 reference

10.1053/J.GASTRO.2010.08.051

https://api.crossref.org/works/10.1053/J.GASTRO.2010.08.051

6 July 2024

Clinical trial: pharmacodynamics and pharmacokinetics of re-treatment with fixed-dose induction of peginterferon alpha-2a in hepatitis C virus genotype 1 true non-responder patients.

11

1 reference

10.1053/J.GASTRO.2010.08.051

https://api.crossref.org/works/10.1053/J.GASTRO.2010.08.051

6 July 2024

Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirin

12

1 reference

10.1053/J.GASTRO.2010.08.051

https://api.crossref.org/works/10.1053/J.GASTRO.2010.08.051

6 July 2024

Histological grading and staging of chronic hepatitis

13

1 reference

10.1053/J.GASTRO.2010.08.051

https://api.crossref.org/works/10.1053/J.GASTRO.2010.08.051

6 July 2024

Design and validation of a histological scoring system for nonalcoholic fatty liver disease

14

1 reference

10.1053/J.GASTRO.2010.08.051

https://api.crossref.org/works/10.1053/J.GASTRO.2010.08.051

6 July 2024

Impact of high-dose peginterferon alfa-2A on virological response rates in patients with hepatitis C genotype 1: a randomized controlled trial

15

1 reference

10.1053/J.GASTRO.2010.08.051

https://api.crossref.org/works/10.1053/J.GASTRO.2010.08.051

6 July 2024

Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirin

16

1 reference

10.1053/J.GASTRO.2010.08.051

https://api.crossref.org/works/10.1053/J.GASTRO.2010.08.051

6 July 2024

Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial

17

1 reference

10.1053/J.GASTRO.2010.08.051

https://api.crossref.org/works/10.1053/J.GASTRO.2010.08.051

6 July 2024

Induction pegylated interferon alfa-2b in combination with ribavirin in patients with genotypes 1 and 4 chronic hepatitis C: a prospective, randomized, multicenter, open-label study

18

1 reference

10.1053/J.GASTRO.2010.08.051

https://api.crossref.org/works/10.1053/J.GASTRO.2010.08.051

6 July 2024

Weight-related effects on disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial

19

1 reference

10.1053/J.GASTRO.2010.08.051

https://api.crossref.org/works/10.1053/J.GASTRO.2010.08.051

6 July 2024

Effect of significant histologic steatosis or steatohepatitis on response to antiviral therapy in patients with chronic hepatitis C.

20

1 reference

10.1053/J.GASTRO.2010.08.051

https://api.crossref.org/works/10.1053/J.GASTRO.2010.08.051

6 July 2024

Hepatic steatosis is a predictor of poor response to interferon alpha-2b and ribavirin combination therapy in Japanese patients with chronic hepatitis C.

21

1 reference

10.1053/J.GASTRO.2010.08.051

https://api.crossref.org/works/10.1053/J.GASTRO.2010.08.051

6 July 2024

Clinical implications of hepatic steatosis in patients with chronic hepatitis C: a multicenter study of U.S. veterans

22

1 reference

10.1053/J.GASTRO.2010.08.051

https://api.crossref.org/works/10.1053/J.GASTRO.2010.08.051

6 July 2024

Hepatic steatosis in patients with chronic hepatitis C virus genotype 2 or 3 does not affect viral response in patients treated with peginterferon alpha-2a (40KD) (PEGASYS) plus ribavirin (COPEGUS) for 16 or 24 weeks

23

1 reference

10.1053/J.GASTRO.2010.08.051

https://api.crossref.org/works/10.1053/J.GASTRO.2010.08.051

6 July 2024

Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C.

24

1 reference

10.1053/J.GASTRO.2010.08.051

https://api.crossref.org/works/10.1053/J.GASTRO.2010.08.051

6 July 2024

Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin.

25

1 reference

10.1053/J.GASTRO.2010.08.051

https://api.crossref.org/works/10.1053/J.GASTRO.2010.08.051

6 July 2024

ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C.

26

1 reference

10.1053/J.GASTRO.2010.08.051

https://api.crossref.org/works/10.1053/J.GASTRO.2010.08.051

6 July 2024

Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic response

27

1 reference

10.1053/J.GASTRO.2010.08.051

https://api.crossref.org/works/10.1053/J.GASTRO.2010.08.051

6 July 2024

Identifiers

10.1053/J.GASTRO.2010.08.051

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42999649&oldid=2197053883"